Skip to main content
TTrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor.

Phase 3 Systemic Lupus Erythematosus Trials

9 Phase 3 trials for Systemic Lupus Erythematosus. Phase 3 trials are the final stage of testing before a treatment can be submitted for FDA approval.

What is a Phase 3 trial?

Phase 3 clinical trials study a treatment in large groups (hundreds to thousands of people) to confirm its effectiveness, monitor side effects, and compare it to standard treatments. These trials are the last major step before the FDA considers approving a new treatment.

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.
RECRUITINGPhase 3NCT04702256

Induction Therapy for Lupus Nephritis With no Added Oral Steroids: A Trial Comparing Oral Corticosteroids Plus...

This is a randomised, open label, controlled non-inferiority phase III multicentre trial. As primary objective, the study aims to demonstrate that a regimen free of additional...

Sponsor: Assistance Publique - Hôpitaux de ParisEnrolling: 1961 location
RECRUITINGPhase 3NCT06015737

A Phase III Study to Investigate the Efficacy and Safety of Anifrolumab in Adults With Chronic and/or Subacute...

This study aims to evaluate the efficacy and safety of subcutaneous (SC) anifrolumab versus placebo in adult participants with chronic and/or subacute cutaneous lupus...

Sponsor: AstraZenecaEnrolling: 30220 locations
RECRUITINGPhase 3NCT05648500

A Research Study to Evaluate the Effects of a New Oral Medicine Called Cenerimod in Adults With Systemic Lupus...

The goal of this clinical trial is to see how well cenerimod reduces symptoms of Systemic Lupus Erythematosus in adult patients with moderate to severe symptoms. The main...

Sponsor: Viatris Innovation GmbHEnrolling: 42020 locations
RECRUITINGPhase 3NCT07355218

A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease (ELOWEN-2)

The purpose of this global, multicenter, Phase 3 study is to evaluate the efficacy and safety of enpatoran over 24 weeks in participants with active cutaneous manifestations of...

Sponsor: EMD Serono Research & Development Institute, Inc.Enrolling: 2022 locations
RECRUITINGPhase 3NCT05126277

Safety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With...

This trial will evaluate efficacy, safety, and tolerability of subcutaneous (s.c.) ianalumab given every 4 weeks (q4w) or every 12 weeks (q12w) compared to placebo, in combination...

Sponsor: Novartis PharmaceuticalsEnrolling: 46220 locations
RECRUITINGPhase 3NCT06904729

Chimeric Antigen Receptors T Cells for Refractory/Recurrent Lupus Nephritis in Children

The goal of this prospective, open, single-arm clinical trial was to evaluate the safety and potential efficacy of CAR T cell therapy in children with refractory/recurrent lupus...

Sponsor: Guangzhou Women and Children's Medical CenterEnrolling: 501 location
RECRUITINGPhase 3NCT05843643

Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With...

Systemic Lupus Erythematosus (SLE) is an immune-mediated disease associated with inflammation of multiple organ systems. This study will assess how safe and effective upadacitinib...

Sponsor: AbbVieEnrolling: 100020 locations
RECRUITINGPhase 3NCT06133972

Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus...

The purpose of this study is to evaluate long-term safety and tolerability of ianalumab in participants with systemic lupus erythematosus who have previously completed the...

Sponsor: Novartis PharmaceuticalsEnrolling: 55020 locations
RECRUITINGPhase 3NCT06406205

A Study of QLG1074 Combined With Background Therapy in Subjects With Active Lupus Nephritis

The purpose of this study is to assess the efficacy of QL1074 compared with placebo in achieving renal response after 52 weeks of therapy in subjects with Active Lupus Nephritis.

Sponsor: Qilu Pharmaceutical Co., Ltd.Enrolling: 27010 locations